Related Experiment Videos
AdGVVEGF121.10 (GenVec)
1Clinic for Bone Marrow Transplantation and Hematology/Oncology, Idar-Oberstein, Germany. nbasara@bmt-center-io.com
Current Opinion in Investigational Drugs (London, England : 2000)
|September 27, 2001
Summary
GenVec is developing AdGVVEGF121.10, a gene therapy using vascular endothelial growth factor (VEGF), for coronary and peripheral vascular diseases. Phase II trials are underway to assess its efficacy and safety in patients.
Area of Science:
- Gene Therapy
- Cardiovascular Medicine
- Molecular Biology
Background:
- Coronary artery disease (CAD) and peripheral vascular disease (PVD) represent significant unmet medical needs.
- Gene therapy offers a novel approach to treating vascular diseases by targeting angiogenesis.
- Vascular endothelial growth factor (VEGF) plays a crucial role in blood vessel formation.
Purpose of the Study:
- To evaluate the safety and efficacy of AdGVVEGF121.10 gene therapy for CAD and PVD.
- To assess the impact of AdGVVEGF121.10 on exercise capacity and patient well-being in severe CAD patients.
- To investigate the drug tolerance and therapeutic potential of VEGF121 gene transfer.
Main Methods:
- Phase II clinical trials are being conducted for both CAD and PVD.
- The initial CAD trial involves approximately 70 patients with severe disease ineligible for surgery.
- Assessments include exercise capacity, patient well-being, safety, and drug tolerance pre- and post-treatment.
Main Results:
- Phase II trials for CAD commenced by March 2000.
- Phase II trials for PVD were initiated by August 2000.
- GenVec was awarded a patent for vectors targeting gene transfer to specific tissues.
Conclusions:
- AdGVVEGF121.10 (BioBypass) shows promise as a gene therapy for vascular diseases.
- Clinical trials are progressing to determine the therapeutic value of VEGF121 gene transfer.
- The development of AdGVVEGF121.10 is a collaborative effort involving GenVec, Pfizer, and Scios.